



Ventripoint Announces Filing of Articles of Amendment

Toronto, Ontario – The Newswire – January 13, 2021 - Ventripoint Diagnostics Ltd. ("**Ventripoint**" or the "**Company**"), (TSXV:VPT; OTC:VPTDF) announces it has filed articles of amendment in accordance with the Canada Business Corporations Act to change the province in which the registered office of the Company is located from Alberta to Ontario. Shareholders of the Company approved the amendment at the annual and special meeting of shareholders held on December 14, 2020.

A copy of the articles of amendment will be posted on the Company's issuer profile on SEDAR at www.SEDAR.com

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Dr. George Adams

gadams@ventripoint.com

Tel: 519-803-6937

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.